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Stroke is the third commonest cause of death and the major cause of adult neurological disability worldwide. While much is known
about conventional risk factors such as hypertension, diabetes and incidence of smoking, these environmental factors only account
for a proportion of stroke risk. Up to 50% of stroke risk can be attributed to genetic risk factors, although to date no single risk
allele has been convincingly identified as contributing to this risk. Advances in the field of genetics, most notably genome wide
association studies (GWAS), have revealed genetic risks in other cardiovascular disease and these techniques are now being applied
to ischaemic stroke. This review covers previous genetic studies in stroke including candidate gene studies, discusses the genome
wide association approach, and future techniques such as next generation sequencing and the post-GWAS era. The review also
considers the overlap from other cardiovascular diseases and whether findings from these may also be informative in ischaemic
stroke.
1. Evidence for Genetic Factors in Stroke Risk
Stroke is the third commonest cause of death and the
major cause of adult neurological disability, aﬀecting both
the developed world and increasingly having an impact in
the developing world as well. It is also a major cause of
dementia and the commonest cause of late onset epilepsy.
Therefore, increasing our understanding of the risks, causes,
and treatment of ischaemic stroke is of great importance.
Stroke is itself a syndrome cause by a number of diﬀerent
disease processes. About 80% of strokes are ischemic and
20% are due to primary hemorrhage. In this paper we will
only address the genetics of ischaemic stroke. While much is
known about conventional risk factors such as hypertension,
diabetes, and incidence of smoking, studies suggest these
only account for a proportion of ischaemic stroke risk.
Considerable evidence suggests genetic predisposition may
explain some of the remaining risk, including evidence from
both twin and family studies [1]. Family studies have shown
diﬀerential association with diﬀerent subtypes of stroke,
suggesting these may have diﬀerent underlying genetic risk
factors [2, 3].
Further evidence for a genetic contribution to ischaemic
stroke risk comes from animal models [4] and from the study
of intermediate phenotypes such as carotid artery intima-
media thickness (IMT) as a marker for large artery disease
and MRI white matter hyperintensities as a marker for small
vessel stroke. Twin and family history studies have shown
these both have significant heritability (the proportion of
stroke risk attributable to genetic risk factors) with estimates
ranging from 55–71% for IMT [5–7] and 30–68% for WMH
[8–10]. The identification of genetic variants predisposing
to known stroke risk factors such as atrial fibrillation (AF)
[11] and myocardial infarction (MI) and coronary artery
disease (CAD) [12] further highlights the role of genetic
predisposition in stroke risk.
The clearest evidence that genetics can cause ischaemic
stroke comes from monogenic forms of the disease, although
these account for only a relatively small percentage of overall
ischaemic stroke incidence [13] and appear to have limited
relevance to common polygenic stroke. As such they will
not be considered as part of this paper in detail, but are
covered in reviews elsewhere [14]. Therefore, considerable
evidence suggests genetic factors do play an important role
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in ischaemic stroke, so why have so few genes been identified
that contribute to this risk and why have other fields,
including related cardiovascular disease phenotypes, been
more successful?
2. Identification of Genetic Risk:
Candidate Gene and Familial Linkage Studies
Until recently, identification of genetic variants contributing
to disease has been attempted by 2 main techniques—
candidate gene studies and familial linkage studies (See Box 1
for details of the diﬀerent types of genetic investigation
and their use). Of these, the candidate gene study has
been the mainstay of genetic investigation into the vast
majority of polygenic diseases thought to have a genetic
component. Typically, a gene identified as a “candidate” is
hypothesised to be involved in stroke risk, and then, genetic
variants, usually single nucleotide polymorphisms (SNPs),
are identified within that gene. The frequency of the SNPs
is then determined in a series of cases and controls and the
two compared.
The vast majority of candidate gene studies in ischaemic
stroke have turned out to be disappointing. Reasons for
this include insuﬃcient sample size, a failure to replicate
results initially reported as significant, poor stroke subtyping
or phenotyping, and a failure to look for associations with
specific subtypes of stroke [15]. Meta-analysis of published
candidate gene studies has revealed some consistently posi-
tive findings however, such as Factor V Leiden Arg506Gln,
MTHFR C677T and the ACE insertion/deletion polymor-
phism [16], although caution is required in interpretation
due to the possible eﬀect of publication bias meaning positive
studies are more likely to be published. Although still useful
when explaining specific hypotheses, candidate gene studies
have now been largely superseded by the genome-wide
association study (GWAS) technique.
Familial linkage studies examine genetic variants through
multiple generations of families and correlate these with
disease incidence. Associations with a specific gene are not
sought using this approach, but rather one looks for variants
anywhere in the entire genome, and they are therefore
referred to as “nonhypothesis driven” experiments. The
technique has had, and continues to have, great success
in identifying genes underlying Mendelian disorders in
monogenic conditions where a single gene contributes the
entirety of genetic risk. Familial linkage studies rely on
collection of families with the disease however, and this is a
challenge in stroke where the late age of onset means parents
are often not alive; this has hampered collection of cases
in studies such as the siblings with ischaemic stroke study
(SWISS) [17, 18].
One notable exception to this has been in Iceland, where
the DeCode group reported identification of the first genetic
risk for common polygenic ischaemic stroke via such a famil-
ial linkage study, which they named STRK1 [19]. This study
used the unique national collection of genealogical samples
and family structures tracked in the Icelandic population
to retrospectively determine cause of death and provide
material for genotyping. The STRK1 locus was identified as
overlying the gene phosphodiesterase4D (PDE4D), a cyclic
AMP regulator which is a plausible biological candidate [19].
Subsequent replication in European cohorts failed to confirm
these findings [20]. This study was undertaken as large-
scale genome-wide experiments were being developed as a
mainstream technique. By current standards the DeCode
finding would today be considered underpowered as it failed
to exceed the currently agreed statistical threshold for such
studies.
3. Identification of Genetic Risk:
The Genome Wide Association Study
The field of complex genetics has been revolutionized by the
advent of the genome-wide association study (GWAS) [21].
This can be thought of as a large series of candidate gene
studies performed in a single experiment on an array based
format. As many as 1.2 million polymorphisms at a time can
now be studied in this manner. Crucially, these are spread
throughout the entire genome and such experiments are
thus nonhypothesis driven, overcoming a major limitation
of the candidate gene study. Such a large number of
experiments in a single study requires a large sample sizes
to allow suﬃcient power, even after statistical correction for
multiple comparisons. Also crucial to progress has been the
realisation that careful phenotyping is important, and that
associations should be replicated in a second population
before publication.
An early demonstration of the power of this technique
was in age-related macular degeneration, a late onset
eye disorder leading to blindness in which conventional
cardiovascular risk factors play a part. Applying a GWAS
approach to this condition revealed associations with the
complement factor H gene, and identification of a single
amino acid substitution which proved to be the causal
variant in this condition [22]. Interestingly, the same locus
had been identified by a familial linkage approach in previous
studies, but refinement of the region and identification of the
causal variant via familial linkage had been impossible.
As a consequence of this and other studies, the enormous
potential of GWAS to identify common variants associated
with common diseases became recognised, with perhaps the
seminal GWAS publication by the Wellcome Trust Case Con-
trol Consortium 1 study making GWAS a mainstream tech-
nique in disease gene identification [23]. This study exam-
ined 14,000 cases of seven common diseases and 3,000 shared
controls in an eﬀort to identify genetic variants in human dis-
ease. Investigating bipolar disorder, coronary artery disease,
Crohn’s disease, hypertension, rheumatoid arthritis, and
type I and type II diabetes, this single study identified over
58 novel loci as potentially contributing genetic risk in these
conditions. To date, the GWAS technique has identified over
1212 new genetic loci predisposing to common polygenic
disease (http://www.genome.gov/gwastudies). Novel genetic
associations with a range of cardiovascular phenotypes
including myocardial infarction, coronary artery disease,
diabetes and hyperlipidaemia have been reported, but few
variants have been confirmed for ischaemic stroke.
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The figure shows number of publications per year identified with the search terms “genetic linkage”, “candidate gene”, “genome wide
association study”, and “next generation sequencing” according to PUBMED as of March 2011. The figure shows linkage studies
appear to have peaked and are now in decline, while the term candidate gene is still in common usage, although it now typically
refers to any gene identified as a plausible cause of disease however identified rather than as a type of study in its own right. The term
“genome wide association study” has the steepest gradient indicating a rapid reporting of findings using this technique, and next
generation sequencing is too new a term to have really made an impact on the literature yet.
Genetic Linkage. A technique which examines genetic variants through multiple generations of the same family and examines
incidence with disease status. A powerful technique for Mendelian diseases where a single gene controls the phenotype, genetic
linkage has had relatively little success in ischaemic stroke due to the late age of onset and lack of large pedigrees with multiple
aﬀected individuals available for meaningful study.
Candidate Gene Study. A gene hypothesised to be involved in or a risk factor for any disease with a genetic basis. Originally
candidate gene study referred to a specific type of study whereby genes were typically identified on the basis of biological plausibility
for the disease in question and then examined single for genetic variants at that one locus in a so called hypothesis driven manner.
More recently the advent of candidate gene has evolved to include any gene identified from range of genetic investigations rather
than referring to a particular type of study specifically. Its usage in the literature is commonplace and maintained for this reason.
Genome Wide Association Study. A technique which looks at multiple genetic variants, typically between 300,000 and 1 million at
a time in a single experiment, in a nonhypothesis driven manner. The variants are spread throughout the genome at random
and allows systematic investigation of a large number of regions in cases and controls. The technique relies on association of specific
alleles with disease state. Unlike genetic linkage, individuals are not related, thus requiring large, typically several thousand, cases
and controls for comparison. Although complex and expensive, this technique has identified more loci than any other for common
polygenic disease under the Common Variant Common Disease (CVCD) hypothesis.
Next Generation Sequencing. Defined as next generation since it uses the same array based format as genome-wide association arrays
rather than more traditional liquid based Sanger sequencing, NGS is currently the cutting edge technology available for direct
sequencing of DNA. Allowing determination of the entire exome (coding portion) of the human genome in a single experiment,
NGS is being used to examine the Rare Variant, Common Disease (RVCD) hypothesis. Although expensive, since it relies on the
identification of rare variants far fewer individuals are required for studies. Current advances in multiplexing of samples by labeling
with genetic tags before sequencing allows mixing of samples and a reduction in cost.
Box 1: Types of analysis for genetic investigation.
It should be noted that while GWAS is a powerful
technique, it requires very large, well phenotyped case
series—typically in the thousands of samples, and even with
these sample sizes is powered only to detect modest risks,
typically with odds ratios in the region of 1.2–1.5. Thus the
contribution of each risk locus to overall disease incidence
is likely to be minor, although these risks are additive and
as such identification of multiple loci may allow individual
risk profiles to be determined. Identification of high risk
individuals could be useful in early intervention to reduce
conventional risk factors, more rigorous screening for early
signs of disease and in investigating severity of disease at
onset as well as associations with disease recurrence.
4. GWAS and Ischaemic Stroke
While GWAS has contributed greatly to identification of
genetics of many complex diseases over the last 5 years,
application of the technique to ischaemic stroke has been
slower, with large-scale collaborative eﬀorts only now begin-
ning to emerge. An early study applied the GWAS technique
to 249 ischaemic stroke cases and 268 controls, but we now
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realize this was underpowered [24]. A more recent study
in prospective population-based cohorts identified a region
on Chromosome 12 overlying the NINJ2 gene in ischaemic
stroke cases [25], although a subsequent large replication
failed to confirm this finding [26].
The collection of large, well phenotyped sample cohorts
for genetic analysis in stroke presents major challenges. In
particular phenotyping, which we now realize is essential,
requires detailed and expensive investigations. As in other
complex diseases, collection of suﬃciently large sample
sizes depends on larges scale international collaborations,
and to address this the International Stroke Genetics Con-
sortium (ISGC—http://www.strokegentics.org/) was estab-
lished. Currently an ischaemic stroke GWAS in 4000 cases is
near completion as part of the Wellcome Trust Case Control
Consortium 2 study (WTCCC2) in collaboration with the
ISGC. GWAS studies in countries including the US and
Australia are also ongoing with results expected in 2011. A
lesson from other disease areas is that, even with sample
sizes of several thousands, power is limited and meta-analysis
of multiple GWAS studies has become standard practice.
The Meta-stroke collaboration has been formed in ischaemic
stroke to address this.
These collaborative eﬀorts have achieved early success
in ischaemic stroke via examination of genetic associations
already identified in related cardiovascular diseases. The
identification of a region on Chromosome 9p21 in myocar-
dial infarction and coronary artery disease, which surrounds
the CDKN2A and CDKN2B genes, has generated a large
amount of interest [27]. An examination of this locus in
a candidate gene study in ischaemic stroke cases revealed
an association with large artery stroke, but not the other
ischaemic stroke subtypes [28]. This association persisted
across multiple populations and importantly emphasises the
likely diﬀering contributions of genetic risks to diﬀerent
ischaemic stroke subtypes.
Two genetic variants identified as contributing to the risk
of atrial fibrillation (AF), in the genes PITX2 and ZFHX3,
have also been shown to associate with cardioembolic stroke
risk for which AF is an important risk factor [29, 30]. As new
loci are identified for other cardiovascular diseases which
themselves are associated with stroke, rapid testing these in
stroke populations via large International collaborations is
possible.
5. Recommendations for Future Genetic
Studies in Stroke
Previous studies in stroke genetics have been disappointing.
There are a number of reasons for this, most significant
of which are poor phenotyping, small sample sizes, and
failure to replicate initial findings in a second population.
Any future genetic study, whether hypothesis driven or
nonhypothesis driven, should address each of these issues
prior to publication. Power calculations demonstrating the
number of cases required for confirmation or refutation
of a finding should be included to allow an estimate of
the significance and robustness of the findings presented.
Genetic risks in stroke are usually estimated to be between
1.1 and 1.5 for a single loci, and studies should be adequately
powered (i.e., be comprised of suﬃcient cases) to detect
risks of this size. Replication of positive associations prior to
publication is important. This should be in a separate case
series using a diﬀerent control set.
Increasing evidence suggests genetic risks diﬀer depend-
ing on ischaemic stroke subtype. Future genetic studies
should therefore include reference to subtypes and subtype
specific risks. Evidence of genetic risk in a homogenous
population of ischaemic stroke without subtype investigation
is likely to lead to spurious associations.
While these measures lead to increased cost and complex-
ity of studies, it is only through such robust experimental
procedures that we will truly begin to understand the genetic
risks of stroke and how these are manifest.
6. The Post GWAS Era in Stroke Genetics
Genome-wide association studies have been specifically
conceived to address the common variant, common disease
(CVCD) hypothesis. This concept underlies the majority
of genetic studies to date not just in stroke but in other
common diseases. According to the CVCD hypothesis,
multiple genetic risk factors contribute to disease, each with
a small additional increase in risk. These risks are additive
in nature and together provide an individual risk profile that
allows for a significant genetic contribution. In order for this
hypothesis to hold true however, variants have to be common
in the population.
Despite the success of GWAS in identifying susceptibility
loci, for the vast majority of diseases these account for only
a fraction of the heritability initially attributed to genetic
risk factors. Each risk identified carries a much smaller risk
than originally thought under the CVCD hypothesis. For
this reason the CVCD theory of genetic risk is now being
questioned, and various mechanisms have been suggested to
account for this “missing heritability” [31]. An alternative
hypothesis is that rare variants are important in common
disease risk (RVCD). This states that as well as common
variants that each contribute very small risks, susceptible
individuals may carry variants of higher risk which are
rare and perhaps even private to themselves or closely
related family members. Such risks would not be detectable
via classical familial linkage since there would be multiple
risk variants contributing to an individuals susceptibility
to disease, but neither would they be detectable via GWAS
since they would be specific to individuals or closely related
family members and therefore not carried by the rest of the
population. Under this hypothesis any one individual would
be expected to carry many variants detectable by GWAS, and
a handful of higher risk alleles in a private manner. Together
these combine to produce an individuals overall risk profile
of disease susceptibility, and may account for the so called
“hidden heritability” conundrum which persists after GWAS.
Identification of these rare variants requires a sequencing
approach which provides information on every base pair
across the region of interest, and this approach is provided
by next generation sequencing (NGS).
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NGS has arisen from both advances in technology, and
from our ability to sequence the human genome as a conse-
quence of the human genome project (http://www.hapmap
.org/) and the 1000 genome (http://www.1000genomes.org/)
project among others. It is now possible to obtain the
entire coding sequence of the human genome in less than
a week, and to make comparisons between genomes due to
advances in computational methods and processing power.
Sequencing of targeted regions at a previously unparalleled
depth and fold coverage without the need for generation
of vector libraries or bacterial culture is now routine and
provided by a number of service providers using a variety of
techniques [32]. While currently expensive, such techniques
give access to perhaps the majority of the information that
conventional genetics can be expected to provide, namely the
entire coding sequence of the genome. Interpretation of that
sequence is still in its relative infancy.
7. Beyond Genomics in Identifying
Ischaemic Stroke Risk Factors
Understanding the genetic basis of disease risk requires an
understanding of the way in which these genes have their
eﬀects in the body. Genes code for RNA, which is then
translated into protein. These proteins can act alone, in
multiples of themselves as homodimers or in conjunction
with other proteins to form heterodimers. Similarly genes
may interact with each other, so called epigenetics, or may
interact with environmental factors in gene-environment
interactions which only aﬀect disease risk when both the
environmental and genetic components of the interaction
are present. Detecting such gene-gene or gene-environment
interactions requires much larger sample sizes. Their impor-
tance has been shown in other cardiovascular diseases
[33] and in association studies with the quantitative trait
continuous carotid IMT [34].
Examination of RNA and proteins in a nonhypothesis
driven manner, similar to GWAS for DNA, is also possible.
Examination of the transcriptome is a relatively old tech-
nique via the use of microarrays, and it is this technology
which actually led to the development of GWAS using DNA
slides or cartridges rather than RNA and cDNA-based ones.
More recently studies have been examining the possibility of
ignoring the DNA level and trying to perform transcription
profiling (examination of all the RNA’s being produced at
a specific time point). By examining changes in the level of
transcription of a subset of RNAs and correlating these with
changes in disease state, disease subtype or disease severity,
we may be able to better understand how genetic diﬀerences
influence disease processes [35].
There are reports that it is possible to diﬀerentiate
between diﬀerent stroke subtypes using this methodology,
with expression levels of just 23 genes being able to diﬀer-
entiate between cardioembolic stroke and large vessel disease
[36]. While such studies are not yet able to replace con-
ventional investigative techniques for determining ischaemic
stroke subtype, identification of a expression profiles may
give novel insights into stroke pathogenesis, and perhaps
identification of suitable biomarkers for monitoring risk
reduction treatments. This technique has also been applied
to associated phenotypes such as white matter hyperintensity
in the brain, currently only detectable by MRI [37].
8. Conclusions
Considerable evidence suggests genetic factors are important
in ischaemic stroke risk. The advent of new techniques such
as GWAS has contributed enormously to the understanding
of the genetics of other complex disease and progress is
just beginning to be made in stroke. For success large, well
phenotyped case cohorts are required, and international
collaborations are essential. NGS technology and techniques
such as transcription profiling and proteomics will allow
us to look for rarer variants in stroke cases and attempt
to identify how these exert their eﬀects at the molecular
level, but whether these will be important remains to be
determined.
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